|
| Status |
Public on May 15, 2024 |
| Title |
PAI-1 Treatment Replicate 1 |
| Sample type |
RNA |
| |
|
| Source name |
PAI-1-treated MDA-MB-231 Cells
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: MDA-MB-231 cell
treatment: PAI-1 treatment
|
| Treatment protocol |
Total RNA extracted using Trizol following manufacturer's instructions
|
| Growth protocol |
MDA-MB-231 cells were kept in an undifferentiated, pluripotent state by using 1000 IU/ml leukemia inhibitory factor (LIF; Chemicon, ESGRO, ESG1107), and grown on top of murine embryonic fibroblasts feeder layer inactivated by 10 ug/ml of mitomycin C (Sigma, St. L
|
| Extracted molecule |
total RNA |
| Extraction protocol |
10 µg of total RNA were primed with 2 µl of 100 µM T16N2 DNA primer at 70°C for 10 min, then reversed transcribed at 42°C for 1 h in the presence of 400 U SuperScript II RTase (Invitrogen), and 100 µM each dATP, dTTP, dGTP, with 25 µM dCTP, 25 µM Cy3-label
|
| Label |
Cy5
|
| Label protocol |
Oligoarray control targets and hybridization buffer (Agilent In Situ Hybridization Kit Plus) were added, and samples were applied to microarrays enclosed in Agilent SureHyb-enabled hybridization chambers. After hybridization, slides were washed sequential
|
| |
|
| Hybridization protocol |
Scanned on an Agilent G2565AA scanner.
|
| Scan protocol |
Images were quantified using Agilent Feature Extraction Software (version A.8.5.1.1).
|
| Data processing |
Agilent Feature Extraction Software (v 8.5.1.1) was used for background subtraction and LOWESS normalization.
|
| |
|
| Submission date |
Jul 30, 2021 |
| Last update date |
May 15, 2024 |
| Contact name |
Wenwen Zhang |
| Organization name |
Nanjing Medical University
|
| Street address |
68 Changle Road
|
| City |
Nanjing |
| State/province |
Jiangsu |
| ZIP/Postal code |
210006 |
| Country |
China |
| |
|
| Platform ID |
GPL23646 |
| Series (1) |
| GSE181202 |
SOX2-OT induced by PAI-1 promotes triple-negative breast cancer cells metastasis |
|
